In a new article published in the Journal of Thoracic Oncology, researchers found that when an optimal dose of vascular endothelial growth factor (VEGF) inhibitor cediranib is administered that it may actually improve the effectiveness of chemotherapy treatment. This conclusion means tht previous studies concluding that the VEGF inhibitor had dose limiting side effects may have been premature.
Author of the study, Dr. Ann Tsao stated that, “Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy,” Cediranib operates by latching onto the VEGF receptor sites inside cancer cells thus stopping the proteins from having an impact on those cells. Previous studies have shown that the inhibitors do help to reduce tumor growth in alveolar soft part sarcoma. The next step for the treatment protocol will be phase II clinical trials. Researchers maintain hopes that cediranib will effectively increase chemotherapy efficacy.
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers